BR0316535A - Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina - Google Patents

Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina

Info

Publication number
BR0316535A
BR0316535A BR0316535-3A BR0316535A BR0316535A BR 0316535 A BR0316535 A BR 0316535A BR 0316535 A BR0316535 A BR 0316535A BR 0316535 A BR0316535 A BR 0316535A
Authority
BR
Brazil
Prior art keywords
serotonin
beta
norepinephrine reuptake
pharmaceutical composition
adrenoceptor agonist
Prior art date
Application number
BR0316535-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Ludwig Mehlburger
Martin Michels
Marion Wienrich
Ursula Ebinger
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR0316535A publication Critical patent/BR0316535A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
BR0316535-3A 2002-11-27 2003-11-03 Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina BR0316535A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02026546A EP1424079A1 (en) 2002-11-27 2002-11-27 Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
PCT/EP2003/012225 WO2004047830A2 (de) 2002-11-27 2003-11-03 Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen

Publications (1)

Publication Number Publication Date
BR0316535A true BR0316535A (pt) 2005-10-04

Family

ID=32241298

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316535-3A BR0316535A (pt) 2002-11-27 2003-11-03 Composição farmacêutica de um agonista adrenoceptor beta-3 e um inibidor de reuptake de serotonina e/ou norepinefrina

Country Status (22)

Country Link
US (2) US20050261328A1 (enExample)
EP (4) EP1424079A1 (enExample)
JP (2) JP2006509751A (enExample)
KR (1) KR20050088295A (enExample)
CN (1) CN1717230A (enExample)
AT (1) ATE399005T1 (enExample)
AU (2) AU2003285312A1 (enExample)
BR (1) BR0316535A (enExample)
CA (2) CA2507266A1 (enExample)
CO (1) CO5580754A2 (enExample)
DE (1) DE50310046D1 (enExample)
EA (1) EA009781B1 (enExample)
EC (1) ECSP055814A (enExample)
ES (1) ES2309371T3 (enExample)
HR (1) HRP20050467A2 (enExample)
MX (1) MXPA05005483A (enExample)
NO (1) NO20053088L (enExample)
PL (1) PL376259A1 (enExample)
RS (1) RS20050392A (enExample)
UA (1) UA81931C2 (enExample)
WO (2) WO2004047830A2 (enExample)
ZA (1) ZA200503282B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704527B2 (en) * 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2005042021A2 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
DE10356112A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff
JP2008516909A (ja) * 2004-10-18 2008-05-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用
EP1809591A1 (en) * 2004-10-26 2007-07-25 Kissei Pharmaceutical Co., Ltd. Synthesis of phenoxyacetic acid derivatives
EP1852117A4 (en) * 2005-02-25 2010-10-27 Astellas Pharma Inc SOLIFENACIN CONTAINING PHARMACEUTICAL AGENT
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
EP1769792A1 (de) * 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
US9440003B2 (en) * 2005-11-04 2016-09-13 Boston Scientific Scimed, Inc. Medical devices having particle-containing regions with diamond-like coatings
FR2895259B1 (fr) * 2005-12-22 2008-02-22 Urosphere Sas Methodes de traitement des incontinences urinaires
US20100172988A1 (en) * 2006-01-10 2010-07-08 Kissei Pharmaceutical Co., Ltd. Sustained release preparation and method for production thereof
KR20090005237A (ko) * 2006-05-22 2009-01-12 테바 파마슈티컬 인더스트리즈 리미티드 둘록세틴 염산염 지연 방출형 제제
WO2008020286A2 (en) * 2006-08-14 2008-02-21 Torrent Pharmaceuticals Limited Pharmaceutical compositions of duloxetine
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
US20080226711A1 (en) * 2007-03-12 2008-09-18 Torrent Pharmaceuticals Ltd. Pharmaceutical compositions of duloxetine
WO2009066181A2 (en) * 2007-07-09 2009-05-28 Combino Pharm, S.L. Oral delayed-release duloxentine hydrochloride pellets
SI2216021T1 (sl) * 2007-11-02 2013-01-31 Astellas Pharma Inc. Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
ES2376095B1 (es) * 2008-10-02 2013-01-24 Laboratorios Del Dr. Esteve, S.A. Pellets entéricos de duloxetina.
WO2010053068A1 (ja) * 2008-11-07 2010-05-14 大日本住友製薬株式会社 新規で有用な下部尿路症状治療剤
EP2316432A1 (de) * 2009-10-30 2011-05-04 ratiopharm GmbH Zusammensetzung enthaltend Fesoterodin und Ballaststoffe
EP2377525A1 (en) * 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Duloxetine enteric pellets
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
PE20131341A1 (es) * 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
TW201338772A (zh) * 2012-02-09 2013-10-01 Altherx Inc 藥學組合物
SG11201502104YA (en) * 2012-09-18 2015-05-28 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder voiding dysfunction and other lower urinary tract disorders by using trospium
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CA3000230A1 (en) * 2015-10-15 2017-04-20 Duke University State-dependent peripheral neuromodulation to treat bladder dysfunction
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
EP3448366A1 (en) 2016-04-25 2019-03-06 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2017186593A1 (en) 2016-04-25 2017-11-02 Synthon B.V. Tablets comprising mirabegron and solifenacin
US10478399B2 (en) 2017-10-12 2019-11-19 Synthon B.V. Modified release tablet composition comprising mirabegron
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
IL104567A (en) * 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
CZ126598A3 (cs) * 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
WO1997025311A1 (en) * 1996-01-10 1997-07-17 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
PL328959A1 (en) * 1996-03-11 1999-03-01 Lilly Co Eli Method of treating or preventing interstitial cystitis
US6310103B1 (en) * 1996-07-19 2001-10-30 Bridge Pharma, Inc. S(−)-tolterodine in the treatment of urinary and gastrointestinal disorders
CA2263659A1 (en) * 1996-08-19 1998-02-26 Kissei Pharmaceutical Co., Ltd. Preventive/remedy for frequent urination and urinary incontinence
WO1998021184A1 (en) * 1996-11-14 1998-05-22 Pfizer Inc. Process for substituted pyridines
WO1998022480A1 (en) * 1996-11-18 1998-05-28 Smithkline Beecham Plc Phosphorus containing aryloxy or arylthio propanolamine derivatives
JPH1112171A (ja) * 1997-06-19 1999-01-19 Nisshin Flour Milling Co Ltd 消化器疾患治療薬
ID24062A (id) * 1997-07-25 2000-07-06 Kissei Pharmaceutical Turunan-turunan asam aminoetilfenoksiasetat dan obat untuk mengurangi nyeri dan membantu penyingkiran dalam litiasis saluran air kencing
KR100506568B1 (ko) * 1997-10-17 2006-04-21 아스텔라스세이야쿠 가부시키가이샤 아미드유도체및이의염,및이를포함하는약제학적제제
ATE250570T1 (de) * 1997-12-18 2003-10-15 Kissei Pharmaceutical Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
US6319920B1 (en) * 1998-02-27 2001-11-20 Syntex (U.S.A.) Llc 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives
WO1999051564A1 (en) * 1998-04-06 1999-10-14 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
ATE275126T1 (de) * 1998-04-14 2004-09-15 Kissei Pharmaceutical 2-methylpropionsäure-derivate und sie enthaltende medizinische zubereitungen
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
SK287111B6 (sk) * 1998-08-27 2009-12-07 Pharmacia & Upjohn Ab Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
DK1227806T3 (da) * 1999-11-11 2005-10-31 Pfizer Health Ab Farmaceutisk præparat indeholdende tolterodin og dets anvendelse
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2001093683A1 (en) * 2000-06-07 2001-12-13 Watson Pharmaceuticals, Inc. Treating smooth muscle hyperactivity with (r)-oxybutynin and (r)- desethyloxybutynin
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
MXPA03006003A (es) * 2001-01-02 2005-09-08 Upjohn Co Nuevas combinaciones de farmacos.
GB0102408D0 (en) * 2001-01-31 2001-03-14 Glaxo Group Ltd Chemical compounds
EP1236723A1 (en) * 2001-03-01 2002-09-04 Pfizer Products Inc. Sulfamide derivatives useful as beta3 agonists and pharmaceutical uses thereof
WO2002085871A2 (en) * 2001-04-04 2002-10-31 Wyeth Serotonergic agents with long-acting in vivo effects
WO2003035600A1 (en) * 2001-10-19 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Process for producing benzocycloheptene derivative
WO2003039464A2 (en) * 2001-11-05 2003-05-15 Pharmacia & Upjohn Company Antimuscarinic aerosol
PL372395A1 (en) * 2002-02-19 2005-07-25 Pharmacia Corporation Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence

Also Published As

Publication number Publication date
ATE399005T1 (de) 2008-07-15
ES2309371T3 (es) 2008-12-16
ECSP055814A (es) 2005-08-11
RS20050392A (sr) 2007-04-10
EP1572181A2 (de) 2005-09-14
US20090012161A9 (en) 2009-01-08
US20050261328A1 (en) 2005-11-24
EA200500776A1 (ru) 2005-12-29
EA009781B1 (ru) 2008-04-28
KR20050088295A (ko) 2005-09-05
EP1572181B1 (de) 2008-06-25
UA81931C2 (uk) 2008-02-25
MXPA05005483A (es) 2005-08-16
HRP20050467A2 (en) 2006-06-30
EP1424079A1 (en) 2004-06-02
EP1567149A2 (de) 2005-08-31
WO2004047838A3 (de) 2004-10-28
CN1717230A (zh) 2006-01-04
JP2006509751A (ja) 2006-03-23
WO2004047830A3 (de) 2004-08-19
WO2004047838A2 (de) 2004-06-10
CA2507343A1 (en) 2005-07-14
AU2003289854A1 (en) 2004-06-18
JP2006509752A (ja) 2006-03-23
AU2003285312A1 (en) 2004-06-18
CA2507266A1 (en) 2004-06-10
US20050261369A1 (en) 2005-11-24
CO5580754A2 (es) 2005-11-30
DE50310046D1 (de) 2008-08-07
EP1640000A3 (de) 2007-01-17
ZA200503282B (en) 2006-07-26
WO2004047830A2 (de) 2004-06-10
PL376259A1 (pl) 2005-12-27
NO20053088L (no) 2005-06-23
EP1640000A2 (de) 2006-03-29

Similar Documents

Publication Publication Date Title
WO2004047830A3 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
BRPI0212733B8 (pt) composição farmacêutica compreendendo composto inibidor da recaptação de serotonina, e, uso do mesmo
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
MY134110A (en) Combinations of reboxetine and neuroleptic agents
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
BRPI0410630A (pt) antagonista de nk1
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson&#39;s disease
BRPI0417739A (pt) (s)-2-n-propilamino-5-hidroxitetralina como um agonista d3
BR0207408A (pt) Azóis como inibidores de malonil-coa decarboxilase úteis como moduladores metabólicos
BR0312658A (pt) Derivados de cinamida
BR0306147A (pt) Uso de um composto ou combinação de compostos tendo atividade agonìstica de receptor de dopamina-d2 parcial e atividade inibidora de reabsorção da serotonina e/ou noradrenalina, método para a preparação de uma composição, e, composição
BRPI0411176A (pt) combinação farmacêutica consistindo de modafinil e outra droga
BR0315355A (pt) Método para o tratamento ou prevenção de sintomas de vasomotores em um paciente, composição farmacêutica e utilização de um inibidor de re-apreensão de norepinefrina
BRPI0411665A (pt) uso de agomelatina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica ou kit, e, métodos para o tratamento de doenças ou distúrbios responsivos a um inibidor da recaptação de serotonina e para aumentar e/ou proporcionar inìcio mais rápido do efeito terapêutico de um inibidor da recaptação de serotonina
BR0309406A (pt) Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento
BRPI0414343A (pt) combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina
WO2004052858A3 (en) Inhibitors of monoamine uptake
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
BRPI0411174A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
BRPI0411175A (pt) combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
MY139551A (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
BR0207716A (pt) Composto, formulação farmacêutica, e, método para a inibição de captação de norepinefrina e de serotonina em mamìferos
BRPI0413750A (pt) uso de loxapina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, e, kit

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.